Please login to the form below

Not currently logged in

GSK's Tyverb cleared for use alongside Herceptin

Combination already approved in the Philippines, Russia and Thailand

GSK Tyverb lapatinib oncology

GlaxoSmithKline's Tyverb has been cleared in the EU for use in combination with Roche's Herceptin in patients with HER2-positive, hormone receptor-negative breast cancer.

Approval was based on the results of the EGF104900 trial, which compared Tyverb (lapatinib) plus Herceptin (trastuzumab) to Tyverb alone and found the combination therapy resulted in a significant eight-month increase in overall survival over Tyverb given alone.

Tyverb acts as an intracellular inhibitor of HER2, while Herceptin binds to the extracellular portion of the receptor and it is thought that employing them in tandem achieves better blockade than either drug used alone.

GSK Oncology president Paolo Paoletti said the EU approval "is important for women with this specific type of metastatic breast cancer, who will have now a new treatment option".

Tyverb and Herceptin represent a 'chemotherapy-free' approach to breast cancer, which "has the potential to make a positive impact on the care and survival of these patients," he added.

The combination has also been approved in the Philippines, Russia and Thailand, but ran into a regulatory block in the US.

Last year, GSK withdrew its application for use of the combination in patients who had previously been treated with Roche's drug in the US (where lapatinib is sold as Tykerb) after the FDA asked for more data.

GSK had high hopes for Tykerb when it was first launched in 2007 as an oral alternative to injectable Herceptin, but sales have never lived up to early expectations and the company has struggled to expand the market for the drug.

First half 2013 sales were just £105m ($164m), a fraction of the $3.33bn Herceptin brought in during the same period, and GSK has faced a series of setbacks trying to extend its indications.

In June the company reported disappointing results for Tyverb in a gastric cancer trial, while last year it withdrew an EU application seeking approval in combination with paclitaxel in patients with metastatic HER2-positive breast cancer.

Meanwhile, a trial of the drug as an adjuvant therapy in early breast cancer failed to show a significant improvement in progression-free survival (PFS) compared to placebo.

16th August 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...